CDKN2A is mutated or mis-expressed in about 10% of all melanoma cases (http://cancer.sanger.ac.uk/cosmic), with germline mutations occurring in up to 40% of familial melanoma cases (Rossi et al., 2019), and appears to be a primary mediator of senescence in human nevi (Ross et al., 2011). This evidence concerns the gene CDKN2A and melanoma.